200 related articles for article (PubMed ID: 24859795)
21. Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome.
Moraes RP; Silva JLD; Calado AA; Cavalcanti GA
Int Braz J Urol; 2018; 44(2):338-347. PubMed ID: 29219282
[TBL] [Abstract][Full Text] [Related]
22. Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability.
Abou-Gamrah A; Fawzy M; Sammour H; Tadros S
Arch Gynecol Obstet; 2014 May; 289(5):1023-8. PubMed ID: 24276424
[TBL] [Abstract][Full Text] [Related]
23. Impact of daily number of urgency urinary incontinence episodes on overactive bladder patient reported outcomes.
Angulo JC; Brenes FJ; Lizarraga I; Rejas J; Trillo S; Ochayta D; Arumi D
Actas Urol Esp; 2016 Apr; 40(3):173-82. PubMed ID: 26811022
[TBL] [Abstract][Full Text] [Related]
24. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder.
Gotoh M; Kobayashi T; Sogabe K
Neurourol Urodyn; 2015 Nov; 34(8):730-5. PubMed ID: 25212503
[TBL] [Abstract][Full Text] [Related]
25. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
26. Is there any association between urodynamic variables and severity of overactive bladder in women with idiopathic detrusor overactivity?
Giarenis I; Zacchè M; Robinson D; Cardozo L
Neurourol Urodyn; 2017 Mar; 36(3):780-783. PubMed ID: 27092808
[TBL] [Abstract][Full Text] [Related]
27. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
Dokmeci F; Cetinkaya SE; Seval MM; Dai O
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
[TBL] [Abstract][Full Text] [Related]
28. Validation of the bladder control self-assessment questionnaire (B-SAQ) in men.
Sahai A; Dowson C; Cortes E; Seth J; Watkins J; Khan MS; Dasgupta P; Cardozo L; Chapple C; De Ridder D; Wagg A; Kelleher C
BJU Int; 2014 May; 113(5):783-8. PubMed ID: 24131479
[TBL] [Abstract][Full Text] [Related]
29. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
30. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal changes in overactive bladder and stress incontinence among parous women.
Handa VL; Pierce CB; Muñoz A; Blomquist JL
Neurourol Urodyn; 2015 Apr; 34(4):356-61. PubMed ID: 24633996
[TBL] [Abstract][Full Text] [Related]
32. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
[TBL] [Abstract][Full Text] [Related]
33. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
34. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population.
Lai HH; Shen B; Rawal A; Vetter J
BMC Urol; 2016 Oct; 16(1):60. PubMed ID: 27716241
[TBL] [Abstract][Full Text] [Related]
35. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
Coyne K; Revicki D; Hunt T; Corey R; Stewart W; Bentkover J; Kurth H; Abrams P
Qual Life Res; 2002 Sep; 11(6):563-74. PubMed ID: 12206577
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study.
Vaughan CP; Johnson TM; Ala-Lipasti MA; Cartwright R; Tammela TL; Taari K; Auvinen A; Tikkinen KA
Eur Urol; 2011 Apr; 59(4):629-36. PubMed ID: 21306820
[TBL] [Abstract][Full Text] [Related]
37. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
38. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
39. Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women.
Obloza A; Teo R; Marriott E; Parker G; Tincello D
Int Urogynecol J; 2019 May; 30(5):705-710. PubMed ID: 30306193
[TBL] [Abstract][Full Text] [Related]
40. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
